• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Development Officer Michna Magda covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 10% to 14,444 units (SEC Form 4)

    5/14/25 8:41:13 PM ET
    $STAA
    Ophthalmic Goods
    Health Care
    Get the next $STAA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Michna Magda

    (Last) (First) (Middle)
    25510 COMMERCENTRE DRIVE

    (Street)
    LAKE FOREST CA 92630

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    STAAR SURGICAL CO [ STAA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Development Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/08/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 05/08/2025 F 1,675 D $19.53 14,444(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On May 8, 2023, the reporting person was granted an award of 14,047 restricted stock units (RSUs), subject to vesting as to 1/3 of the shares of common stock subject to such RSUs annually over three years. On May 8, 2025, the RSUs vested as to 4,682 shares, and 1,675 shares were withheld to satisfy taxes.
    2. Includes shares of common stock owned outright and shares of common stock subject to unvested RSUs.
    /s/ Nathaniel Sisitsky as attorney-in-fact for Magda Michna 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $STAA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STAA

    DatePrice TargetRatingAnalyst
    4/21/2025$17.00Equal Weight
    Wells Fargo
    2/12/2025Buy → Hold
    Jefferies
    2/12/2025$45.00 → $17.00Outperform → Neutral
    Mizuho
    2/12/2025Buy → Neutral
    BTIG Research
    2/12/2025Outperform → Mkt Perform
    William Blair
    7/15/2024$50.00 → $37.00Equal-Weight → Underweight
    Morgan Stanley
    6/11/2024$46.00Neutral → Buy
    BTIG Research
    3/11/2024$30.00 → $50.00Hold → Buy
    Stifel
    More analyst ratings

    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STAAR Surgical Announces $30 Million Share Repurchase Authorization

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we

      5/16/25 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Reports First Quarter 2025 Results

      China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due

      5/7/25 4:01:00 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on STAAR Surgical with a new price target

      Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00

      4/21/25 8:38:55 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical downgraded by Jefferies

      Jefferies downgraded STAAR Surgical from Buy to Hold

      2/12/25 11:13:24 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical downgraded by Mizuho with a new price target

      Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously

      2/12/25 7:11:03 AM ET
      $STAA
      Ophthalmic Goods
      Health Care

    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

      SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

      9/6/24 9:51:09 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

      SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

      2/13/24 5:14:04 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

      SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

      1/26/24 9:19:42 AM ET
      $STAA
      Ophthalmic Goods
      Health Care

    $STAA
    Leadership Updates

    Live Leadership Updates

    See more
    • STAAR Surgical Announces Leadership Transition

      Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to

      2/26/25 4:45:00 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

      New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:

      5/1/24 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. "Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry," said Aimee Weisner, Chair

      3/12/24 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care

    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $STAA
    Financials

    Live finance-specific insights

    See more
    • Chief Development Officer Michna Magda covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 10% to 14,444 units (SEC Form 4)

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      5/14/25 8:41:13 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Director Silverman Lou

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      5/13/25 6:04:36 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Director Jiang Wei

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      5/13/25 6:02:43 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • Large owner Broadwood Partners, L.P. bought $2,866,428 worth of shares (187,227 units at $15.31) (SEC Form 4)

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      4/10/25 7:00:22 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • Large owner Broadwood Partners, L.P. bought $13,627,504 worth of shares (845,220 units at $16.12) (SEC Form 4)

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      4/7/25 8:28:12 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • Large owner Broadwood Partners, L.P. bought $941,285 worth of shares (53,969 units at $17.44) (SEC Form 4)

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      4/2/25 8:33:34 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Announces $30 Million Share Repurchase Authorization

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we

      5/16/25 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Reports First Quarter 2025 Results

      China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due

      5/7/25 4:01:00 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $STAA
    SEC Filings

    See more
    • STAAR Surgical Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - STAAR SURGICAL CO (0000718937) (Filer)

      5/16/25 7:00:09 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by STAAR Surgical Company

      10-Q - STAAR SURGICAL CO (0000718937) (Filer)

      5/7/25 4:11:47 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STAAR SURGICAL CO (0000718937) (Filer)

      5/7/25 4:02:55 PM ET
      $STAA
      Ophthalmic Goods
      Health Care